Beyond a singular focus on GLP 1: why we need a new nomenclature now The Lancet Diabetes & Endocrinology Too often, BPC 157 gets boxed into a single use: injury recovery. Gabriel Alizaidy, MD, MS BPC 157 peptide therapy for injury recovery and gut health CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide ( GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current